Oxirane, 2,2',2''-[methylidynetris(phenyleneoxymethylene)]tris- | 66072-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: Oxirane, 2,2',2''-[methylidynetris(phenyleneoxymethylene)]tris-
• 英文别名: 2-[[2-[bis[2-(oxiran-2-ylmethoxy)phenyl]methyl]phenoxy]methyl]oxirane
• CAS: 66072-38-6
• 化学式: C₂₈H₂₈O₆
• 分子量: 460.5
• InChiKey: UJWXADOOYOEBCW-UHFFFAOYSA-N

物化性质

• 熔点：
  48-50 °C(lit.)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  65.3
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• WGK Germany：
  3

文献信息

• Aminoalkohol-basierte Tenside mit geringer Oberflächenspannung und deren Verwendung
  申请人：Goldschmidt AG

  公开号：EP1477473A1

  公开（公告）日：2004-11-17

  Gegenstand der Erfindung sind Aminoalkohol-basierte Tenside mit geringer Oberflächenspannung und deren Verwendung als Tensid in wässrigen Beschichtungsformulierungen, herstellbar durch Umsetzung mindestens eines sekundären Amins gemäß Formel (I): mit mindestens einem Diepoxid gemäß Formel (III): und/oder mindestens einem Triepoxid gemäß Formel (IV): in im wesentlichen äquivalenten Mengen von Aminwasserstoffatomen und Epoxidgruppen.

  本发明涉及基于氨基醇的表面活性剂，其具有较低的表面张力，并且其在水性涂料配方中作为表面活性剂的使用，可通过将至少一种符合以下式（I）的二级胺与至少一种符合以下式（III）的双环氧化物和/或至少一种符合以下式（IV）的三环氧化物在氨基氢原子和环氧基团之间以基本等量的量进行反应而制备。
• Chloroquine combination drugs and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20070060499A1

  公开（公告）日：2007-03-15

  This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

  这项发明揭示了氯喹偶联活性药剂的组合物，包括其制备方法。先前的技术已经表明，以足够高浓度给予氯喹作为游离药物，可以增强细胞内体内各种药剂从细胞内体释放到细胞质中。这些组合物的目的是在传递活性药剂的相同部位提供受控量的氯喹，从而减少所需的总剂量。这些组合物包括将氯喹物质直接或通过各种药用载体物质偶联到活性药剂。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以产生治疗效果的物质。这些组合物还可以包括用于携带和释放活性药剂以用于治疗或其他医疗用途的生物可降解连接。该发明还揭示了与靶向分子偶联的载体组合物，用于将氯喹物质和活性药剂定位传递到它们的作用部位。
• Chloroquine coupled nucleic acids and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20060040879A1

  公开（公告）日：2006-02-23

  This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the nucleic acid needs to be released, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a nucleic acid directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing nucleic acids for therapeutic or other medical uses. The invention also discloses nucleic acid carrier compositions that are coupled to targeting molecules for targeting the delivery of nucleic acids to their site of action.

  本发明披露了制备氯喹偶联核酸组合物的组成和方法。先前的研究表明，以足够高的浓度给予氯喹作为自由药物，可以增强细胞内体内各种物质从内体泡中释放到细胞质中。这些组合物的目的是在核酸需要释放的同一位置提供受控量的氯喹，从而降低所需的总剂量。该组合物包括直接或通过各种药物载体物质偶联的氯喹物质和核酸。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以达到治疗效果的物质。该组合物还可以包括生物可降解连接来携带和释放用于治疗或其他医疗用途的核酸。本发明还披露了偶联到靶向分子的核酸载体组合物，用于将核酸传递到其作用位置。
• Polyether, active-hydrogen ingredient , resin-forming composition, and process for producing foam
  申请人：——

  公开号：US20030100623A1

  公开（公告）日：2003-05-29

  The present invention relates to polyether compounds, active hydrogen compounds and resin-forming compositions composed of the polyols, and methods for producing foams by employing the active hydrogen components. These polyether compounds have a decreased number of moles of added EO thereby maintaining the hydrophobicity and have sufficient reactivity as polyol components of resins, thereby having high reaction rates. Therefore, it is possible to provide resins having excellent resin properties (tensile strength, flexural strength, water-absorption swelling ratio, etc.).

  本发明涉及聚醚化合物、活性氢化合物和由聚醚醇组成的树脂成型组合物，以及通过使用活性氢成分制备泡沫的方法。这些聚醚化合物具有降低的EO加入摩尔数，从而保持疏水性，并具有足够的反应性作为树脂的聚醇组分，因此具有高反应速率。因此，可以提供具有优异树脂性能（拉伸强度、弯曲强度、吸水膨胀率等）的树脂。
• Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom
  申请人：——

  公开号：US20030105268A1

  公开（公告）日：2003-06-05

  A process for manufacturing an &agr;-dihydroxy derivative from an aryl allyl ether wherein such &agr;-dihydroxy derivative can be used to prepare an &agr;-halohydrin intermediate and an epoxy resin prepared therefrom including epoxidizing an &agr;-halohydrin intermediate produced from a halide substitution of an &agr;-dihydroxy derivative which has been obtained by a dihydroxylation reaction of an aryl allyl ether in the presence of an oxidant or in the presence of an oxidant and a catalyst.

  从芳基丙烯醚中制备α-二羟基衍生物的工艺，其中这种α-二羟基衍生物可用于制备α-卤代醇中间体和由此制备的环氧树脂，包括将从α-二羟基衍生物的卤化物取代反应中产生的α-卤代醇中间体环氧化，该α-二羟基衍生物是在氧化剂或氧化剂和催化剂存在下从芳基丙烯醚的双羟基化反应中获得的。